{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:15:22Z","timestamp":1784632522891,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11096-020-01089-y","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T07:04:41Z","timestamp":1594105481000},"page":"1016-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-000X","authenticated-orcid":false,"given":"A.","family":"Provenzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Hospodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Leonardi Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Y.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Butrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"Suppl 5:","key":"1089_CR1","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1093\/cid\/cir153","volume":"52","author":"B Spellberg","year":"2011","unstructured":"Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5:):S397\u2013428.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1089_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.tips.2010.08.002","volume":"31","author":"LD H\u00f6gberg","year":"2010","unstructured":"H\u00f6gberg LD, Heddini A, Cars O. The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol Sci. 2010;31(11):509\u201315.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1089_CR3","first-page":"116","volume":"43","author":"T Kish","year":"2018","unstructured":"Kish T. New antibiotics in development target highly resistant gram-negative organisms. Pharm Ther. 2018;43(2):116\u201320.","journal-title":"Pharm Ther"},{"key":"1089_CR4","unstructured":"World Health Organization (WHO). Antibiotic resistance. http:\/\/www.who.int\/mediacentre\/factsheets\/antibiotic-resistance\/en\/. Accessed 28 April 2020."},{"key":"1089_CR5","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic\/Antimicrobial Resistance (AR\/AMR). Centers for Disease Control and Prevention (CDC). https:\/\/www.cdc.gov\/drugresistance\/index.html. Accessed 28 April 2020."},{"key":"1089_CR6","unstructured":"European Centre for Disease Prevention and Control (ECDC). The bacterial challenge: time to react. European Centre for Disease Prevention and Control (ECDC). https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed 28 April 2020."},{"issue":"4","key":"1089_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1377\/hlthaff.2017.1153","volume":"37","author":"KE Thorpe","year":"2018","unstructured":"Thorpe KE, Joski P, Johnston KJ. Antibiotic-resistant infection treatment costs have doubled since 2002, now exceeding $2 billion annually. Health Aff (Millwood). 2018;37(4):662\u20139.","journal-title":"Health Aff (Millwood)."},{"key":"1089_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2015.06.003","volume":"24","author":"P Fernandes","year":"2015","unstructured":"Fernandes P. The global challenge of new classes of antibacterial agents: an industry perspective. Curr Opin Pharmacol. 2015;24:7\u201311.","journal-title":"Curr Opin Pharmacol"},{"key":"1089_CR9","unstructured":"Tufts Center for the Study of Drug Development (CSDD). Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published. Tufts Center for the Study of Drug Development (CSDD). https:\/\/www.globenewswire.com\/news-release\/2016\/03\/10\/1187518\/0\/en\/Tufts-Center-for-the-Study-of-Drug-Development-Assessment-of-Cost-to-Develop-and-Win-Marketing-Approval-for-a-New-Drug-Now-Published.html. Accessed 28 April 2020."},{"key":"1089_CR10","unstructured":"European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2016 \u2013 Infectious disease surveillance summary, EU\/EEA, 2014 data. European Centre for Disease Prevention and Control (ECDC). https:\/\/www.ecdc.europa.eu\/en\/infectious-diseases-public-health\/surveillance-and-disease-data\/annual-epidemiological-reports. Accessed 28 April 2020."},{"key":"1089_CR11","unstructured":"World Health Organization (WHO). WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization (WHO). http:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/bacteria-antibiotics-needed\/en\/. Accessed 28 April 2020."},{"key":"1089_CR12","unstructured":"US Food and Drug Administration (FDA). FDA Approved Drug Products. US Food and Drug Administration (FDA). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 28 April 2020."},{"key":"1089_CR13","unstructured":"Xtoro [package insert]. Fort Worth, Texas: Alcon Laboratories, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206307s000lbl.pdf. 2014 Nov."},{"key":"1089_CR14","unstructured":"Zerbaxa [package insert]. Lexington, MA: Cubist Pharmaceuticals U.S. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf. 2016 Oct."},{"key":"1089_CR15","unstructured":"Avycaz [package insert]. Verona, 37135 Italy: GlaxoSmithKline Manufacturing S.p.A. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf. 2018 Feb."},{"key":"1089_CR16","unstructured":"Baxdela [package insert]. Lincolnshire, Illinois: Melinta Therapeutics, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000,208611s000lbl.pdf. 2017 June."},{"key":"1089_CR17","unstructured":"Vabomere [package insert]. Teramo, 64100, Italy: Facta Farmaceutici, S.p.A.. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf. 2017 Aug."},{"key":"1089_CR18","unstructured":"Solosec [package insert]. Newark, NJ: Symbiomix Therapeutics LLC. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209363s000lbl.pdf. 2017 Oct."},{"key":"1089_CR19","unstructured":"Zemdri [package insert]. South San Francisco, CA: Achaogen, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210303Orig1s000lbl.pdf. 2018 June."},{"key":"1089_CR20","unstructured":"Xerava [package insert]. Watertown, MA: Tetraphase Pharmaceuticals, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf. 2018 Aug."},{"key":"1089_CR21","unstructured":"Nuzyra [package insert]. Boston, MA: Paratek Pharmaceuticals, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. 2018 Oct."},{"key":"1089_CR22","unstructured":"Recarbrio [package insert].Whitehouse Station, NJ: Merck & Co. Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212819s000lbl.pdf. 2019 Jul."},{"key":"1089_CR23","unstructured":"Xenleta [package insert]. King of Prussia, PA: Nabriva Pharmaceuticals US Inc. https:\/\/www.xenleta.com\/pdf\/xenleta-prescribing-information.pdf. 2019 Aug."},{"key":"1089_CR24","unstructured":"Fetroja [package insert]. Florham Park, NJ: Shionogi US Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf. 2019 Nov."},{"key":"1089_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","volume":"163","author":"RMA Coates","year":"2011","unstructured":"Coates RMA, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163:184\u201394.","journal-title":"Br J Pharmacol"},{"key":"1089_CR26","unstructured":"RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI (GAMECHANGER). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03869437?cond=cefiderocol&draw=2&rank=2. Accessed 28 April 2020."},{"key":"1089_CR27","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","volume":"2","author":"TF Durand-R\u00e9ville","year":"2017","unstructured":"Durand-R\u00e9ville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, et al. ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104.","journal-title":"Nat Microbiol."},{"key":"1089_CR28","unstructured":"Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused by Acinetobacter Baumannii-calcoaceticus Complex (ATTACK). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03894046. Accessed 28 April 2020."},{"key":"1089_CR29","unstructured":"Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization; 2017 (WHO\/EMP\/IAU\/2017.12). https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/258965\/%20WHO-EMP-IAU-2017.11-eng.pdf;jsessionid=17F40BB39895CFB4CC1967D672F218D1?sequence=1. Accessed 28 April 2020."},{"key":"1089_CR30","unstructured":"Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02257918?term=NCT02257918&rank=1. Accessed 28 April 2020."},{"key":"1089_CR31","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1038\/srep11827","volume":"5","author":"GS Basarab","year":"2015","unstructured":"Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827.","journal-title":"Sci Rep."},{"issue":"10","key":"1089_CR32","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1128\/AAC.01016-15","volume":"59","author":"DJ Biedenbach","year":"2015","unstructured":"Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA. In Vitro activity of AZD0914, a novel bacterial DNA gyrase\/topoisomerase IV inhibitor, against clinically relevant gram-positive and fastidious gram-negative pathogens. Antimicrob Agents Chemother. 2015;59(10):6053\u201363.","journal-title":"Antimicrob Agents Chemother."},{"key":"1089_CR33","unstructured":"Zoliflodacin in Uncomplicated Gonorrhoea. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03959527?term=Zoliflodacin&draw=2&rank=2. Accesses 28 April 2020."},{"key":"1089_CR34","unstructured":"A study evaluating efficacy and safety of gepotidacin compared with ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhea. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04010539. Accessed 28 April 2020."},{"issue":"4","key":"1089_CR35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cid\/ciy145","volume":"67","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67(4):504\u201312.","journal-title":"Clin Infect Dis."},{"key":"1089_CR36","unstructured":"A dose-ranging study evaluating the efficacy, safety, and tolerability of GSK2140944 in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria Gonorrhoeae. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02294682?term=NCT02294682&rank=1. Accessed 28 April 2020."},{"key":"1089_CR37","unstructured":"Dose-ranging study of GSK2140944 in the treatment of subjects with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02045797?term=NCT02045797&rank=1. Accessed 28 April 2020."},{"key":"1089_CR38","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","volume":"466","author":"BD Bax","year":"2010","unstructured":"Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466:935\u201340.","journal-title":"Nature."},{"key":"1089_CR39","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1128\/AAC.02820-15","volume":"60","author":"DJ Biedenbach","year":"2016","unstructured":"Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60:1918\u201323.","journal-title":"Antimicrob Agents Chemother."},{"key":"1089_CR40","unstructured":"Safety and efficacy study of ftortiazinon in the treatment of patients with complicated urinary tract infections caused by P. Aeruginosa. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03638830. Accessed 28 April 2020."},{"key":"1089_CR41","unstructured":"Kunda M, Voronina O, Sharapova N, Ryzhova N, Aksenova E, Gintsburg A. Virulence factors of Achromobacter ruhlandii important for host pathogen interaction. [abstract]. https:\/\/2018.febscongress.org\/abstract_preview.aspx?idAbstractEnc=4424170094091096095092424170. Accessed 28 April 2020."},{"key":"1089_CR42","unstructured":"Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas (PRISM-UDR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03582007?cond=murepavadin&draw=2&rank=1. Accessed 28 April 2020."},{"key":"1089_CR43","unstructured":"Pivotal study in VAP suspected or confirmed to be due to Pseudomonas Aeruginosa (PRISM-MDR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03409679?cond=murepavadin&draw=2&rank=2. Accessed 28 April 2020."},{"issue":"4","key":"1089_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","volume":"16","author":"I Martin-Loeches","year":"2018","unstructured":"Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther. 2018;16(4):259\u201368.","journal-title":"Expert Rev Anti Infect Ther."},{"key":"1089_CR45","unstructured":"Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil,Switzerland, 17 July 2020. https:\/\/www.polyphor.com\/news\/corporate-news-details\/?newsid=1800485. Accessed 10 June 2020."},{"key":"1089_CR46","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00253-018-8787-x","volume":"102","author":"FJ Reen","year":"2018","unstructured":"Reen FJ, Guti\u00e9rrez-Barranquero JA, Parages ML, O\u00b4Gara F. Coumarin: a novel player in microbial quorum sensing and biofilm formation inhibition. Appl Microbiol Biotechnol. 2018;102:2063\u201373.","journal-title":"Appl Microbiol Biotechnol."},{"key":"1089_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.micpath.2018.03.055","volume":"118","author":"S Dolatabadi","year":"2018","unstructured":"Dolatabadi S, Moghadam HN, Mahdavi-Ourtakand M. Evaluating the anti-biofilm and antibacterial effects of Juglans regia L. extracts against clinical isolates of Pseudomonas aeruginosa. Microb Pathog. 2018;118:285\u20139.","journal-title":"Microb Pathog"},{"key":"1089_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejmech.2018.03.044","volume":"151","author":"A Kotb","year":"2018","unstructured":"Kotb A, Abutaleb NS, Seleem MA, Hagras M, Mohammad H, Bayoumi A, et al. Phenylthiazoles with tert-Butyl side chain: metabolically stable with anti-biofilm activity. Eur J Med Chem. 2018;151:110\u201320.","journal-title":"Eur J Med Chem."},{"key":"1089_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fmicb.2015.00377","volume":"6","author":"H Venter","year":"2015","unstructured":"Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol. 2015;6:377.","journal-title":"Front Microbiol."},{"issue":"2","key":"1089_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1517\/13543784.2014.848853","volume":"23","author":"Z Xu","year":"2014","unstructured":"Xu Z, Flavin MT, Flavin J. Combating multidrug-resistant gram-negative bacterial infections. Expert Opin Investig Drugs. 2014;23(2):163\u201382.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"1089_CR51","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2016.06.004","volume":"6","author":"AS Chaudhary","year":"2016","unstructured":"Chaudhary AS. A review of global initiatives to fight antibiotic resistance and recent antibiotics\u2019 discovery. Acta Pharm Sin B. 2016;6(6):552\u20136.","journal-title":"Acta Pharm Sin B."},{"key":"1089_CR52","unstructured":"Generating Antibiotic Incentives Now. Department of Health and Human Services. Food and Drug Administration (FDA). https:\/\/www.fda.gov\/media\/110982\/download. Accessed 28 April 2020."},{"key":"1089_CR53","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.ijantimicag.2013.04.007","volume":"42S","author":"NI Paphitou","year":"2013","unstructured":"Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents. 2013;42S:S25\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"15","key":"1089_CR54","doi-asserted-by":"publisher","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","volume":"115","author":"EY Klein","year":"2018","unstructured":"Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463\u201370.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1089_CR55","unstructured":"Global action plan on antimicrobial resistance. World Health Organization (WHO). https:\/\/www.who.int\/antimicrobial-resistance\/global-action-plan\/en\/. Accessed 28 April 2020."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01089-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01089-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01089-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:20:30Z","timestamp":1625617230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01089-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01089-y","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author disclosures"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}